Literature

Interim Analysis of DC/LC Bead Open Surgical Registry in Primary and Metastatic Liver Tumours
Date 10 April 2008, Florence, Italy
Where presented ET/ECIO Satellite Symposium
Author(s) Dr Robert MARTIN, University of Kentucky, Lexington, USA
Resources

Download file

Interim Analysis of Multi-Institutional LC Bead Registry in Primary and Metastatic Hepatic Tumors
Date 18 March 2008, Grand Hyatt Washington, Washington, D.C., USA
Where presented SIR Dinner Symposium
Author(s) Dr Robert Martin
Resources

Download file

A pilot study of trans arterial chemo-embolization (TACE) with drug eluting beads irinotecan (IRI) preloaded (DEBI) for liver metastases (LM) from uveal melanoma (UM): An Italian National Study
Date 25 - 27 January 2008, Florida, USA
Where presented ASCO GI
Author(s) G Fiorentini, C Aliberti, G Benea et al
Resources

Download file

Interim Analysis of a phase III study comparing TACE DC Beads IRI loaded (DEBIRI) with FOLFIRI chemotherapy (CT) for patients with nonresectable colorectal cancer (CRC) liver metastases (LM)
Date 25 - 27 January 2008, Florida, USA
Where presented ASCO GI
Author(s) G Fiorentini, C Aliberti, G Benea et al
Resources

Download file

Biocompatibles Drug-Eluting Bead Scientific Abstracts and Papers at CIRSE 2007
Date September 2007
Where presented Cardiovascular and Interventional Radiology Society of Europe (CIRSE)
Author(s) Biocompatibles
Resources

Download file

TACE with microspheres preloaded with irinotecan of liver metastases (LM) from colorectal cancer (CRC).
Date September 2007
Where presented Cardiovascular and Interventional Radiology Society of Europe (CIRSE)
Author(s) Aliberti, C, Tilli M, Benea G, et al
Resources

Download file

Drug-Eluting Bead with Irinotecan (DEBIRI) Therapy of Hepatic Metastases in Colorectal Cancer
Date September 2007
Where presented Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Congress - Biocompatibles / Terumo Symposium
Author(s) Dr C Aliberti, Professor G Fiorentini
Resources

Download file

Trans Arterial Chemoembolization (TACE) of liver metastases (LM) from colorectal cancer (CRC) using irinotecan-eluting beads
Date January 2007
Where presented Gastrointestinal Cancers Symposium (ASCO GI)
Author(s) Aliberti G
Resources

Download file

Trans Arterial Chemoembolization (TACE) of liver metastases (LM) from colorectal cancer (CRC) using irinotecan-eluting beads
Date January 2007
Where presented ASCO GI
Author(s) Fiorentini, et al
Resources

Download file

Irinotecan In Liver Metastases - the next indication for Drug-Eluting Beads?
Date November 2006
Where presented Interventional News, Educational Supplement
Author(s) Aliberti C (CIRSE 2006)
Resources

Read more

Page 3 of 3 pages  < 1 2 3

Regulatory notices and product safety data

Worldwide (excluding USA and Canada)

DC Bead® is CE marked and is indicated for the treatment of malignant hypervascular tumours and loading with doxorubicin drug. DC Bead® is also indicated for loading with irinotecan for the treatment of metastatic colorectal cancer (mCRC). For full prescribing information please refer to DC Bead instructions for use.

USA

DC Bead is not currently available for sale or distribution in the USA. DC Bead has not been submitted for approval to the FDA.

Canada

DC Bead® with doxorubicin is indicated for trans-arterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC). DC Bead are also intended to be loaded with irinotecan for the purpose of embolization of vessels supplying malignant colorectal cancer metastasised to the liver (mCRC), and delivery of a local, controlled, sustained dose of irinotecan to the mCRC. For full prescribing information please refer to DC Bead Canada Instructions for Use 

Tawain

DC Bead is approved by the Department of Health and is intended to be loaded with Mayne (Hospira) doxorubicin HCI for the purpose of embolisation of vessels supplying malignant hypervascularised tumour(s), and delivery of a local, controlled, sustained dose of doxorubicin.  DC Bead is also indicated for the embolisation of nidus vessels without medication.  Approved size ranges in Taiwan are 300-500µm and 500-700µm.